Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Status:
Completed
Trial end date:
2018-03-19
Target enrollment:
Participant gender:
Summary
This post-marketing surveillance study will assess the safety and efficacy of Lastacaft®
Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic
Conjunctivitis as prescribed as standard of care in clinical practice in Korea.